TY - JOUR
T1 - Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients
AU - Bazinet, Alexandre
AU - Kadia, Tapan M.
N1 - Funding Information:
Dr Kadia has consulted for AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Sanofi-Aventis, and Servier. He has received grants or research support from AbbVie, Agios, Amgen, BMS, Genentech, Jazz, Pfizer, Cel-lenkos, Ascentage, GenFleet, Astellas, and AstraZeneca. He has served on the speaker’s bureau of Cure and has received honoraria from Genzyme. Dr Bazinet has no disclosures.
Publisher Copyright:
© 2022, Millennium Medical Publishing, Inc.. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Standard therapy for acute myeloid leukemia (AML) has long consisted of intensive chemotherapy followed by allogeneic hematopoietic stem cell transplant. Older individuals (≥60 years), who constitute the majority of patients with AML, may not always benefit from such intensive approaches owing to increasing frailty, comorbidities, and a higher incidence of adverse-risk disease features. Recent years have seen major advances in the development of effective low-intensity therapies for AML. Low-intensity induction regimens based on hypomethylating agents, venetoclax, and nucleoside analogues are highly effective and safe. A greater emphasis is being placed on the importance of an accurate genetic classification of AML to identify patients who may benefit from novel targeted therapies, such as FLT3 and IDH inhibitors. Genomic classification also highlights a group of patients with high-risk disease (TP53-mutated), for whom improved treatments are urgently needed. Finally, given that relapse is the major cause of treatment failure in elderly patients with AML, innovative maintenance strategies incorporating targeted therapy are being investigated to delay or prevent relapse. In this article, we provide an updated review of the treatment of AML in older patients.
AB - Standard therapy for acute myeloid leukemia (AML) has long consisted of intensive chemotherapy followed by allogeneic hematopoietic stem cell transplant. Older individuals (≥60 years), who constitute the majority of patients with AML, may not always benefit from such intensive approaches owing to increasing frailty, comorbidities, and a higher incidence of adverse-risk disease features. Recent years have seen major advances in the development of effective low-intensity therapies for AML. Low-intensity induction regimens based on hypomethylating agents, venetoclax, and nucleoside analogues are highly effective and safe. A greater emphasis is being placed on the importance of an accurate genetic classification of AML to identify patients who may benefit from novel targeted therapies, such as FLT3 and IDH inhibitors. Genomic classification also highlights a group of patients with high-risk disease (TP53-mutated), for whom improved treatments are urgently needed. Finally, given that relapse is the major cause of treatment failure in elderly patients with AML, innovative maintenance strategies incorporating targeted therapy are being investigated to delay or prevent relapse. In this article, we provide an updated review of the treatment of AML in older patients.
KW - Acute myeloid leukemia
KW - Elderly
KW - Hypomethylating agents
KW - Low-intensity therapy
KW - Targeted therapy
KW - Venetoclax
UR - http://www.scopus.com/inward/record.url?scp=85123667910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123667910&partnerID=8YFLogxK
M3 - Article
C2 - 35060961
AN - SCOPUS:85123667910
SN - 1543-0790
VL - 20
SP - 37
EP - 46
JO - Clinical Advances in Hematology and Oncology
JF - Clinical Advances in Hematology and Oncology
IS - 1
ER -